National MS Education and Awareness Month is celebrated each year in the US in March, after having been launched in 2003 by ...

During a Case-Based Roundtable® event, Ryan W. Jacobs, MD, discussed a patient who received 2 prior lines of therapy for ...

Now, Honigberg and colleagues describe an orally available, potent and selective inhibitor of the B-cell receptor (BCR) signalling molecule Bruton's tyrosine kinase (BTK), which shows promising ...

Jaypirca is a targeted therapy for CLL and other specific cancers. It is known as a Bruton’s tyrosine kinase inhibitor (BTK inhibitor). BTK is an enzyme that helps certain types of cancer cells ...

Panelists discuss how clinical and patient-specific factors, such as comorbidities, age, and risk profiles, influence the selection of Bruton tyrosine kinase (BTK) inhibitors for treatment-naive ...

Dr Annalisa Morgan reflects on new data on DMTs for RRMS that highlighted the potential of BTK inhibitors such as ...

In this randomized controlled trial, among patients with chronic spontaneous urticaria who continue to have symptoms while on ...

single-arm trial assessed the combination of the therapy and Brukinsa (zanubrutinib), a Bruton tyrosine kinase (BTK) inhibitor, and reported an overall response rate of 67%. The study enrolled ...

TG Therapeutics, Inc.’s TGTX share price has surged by 10.20%, which has investors questioning if this is right time to sell.